Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma

David W. Sant, Wensi Tao, Matthew G. Field, Daniel Pelaez, Ke Jin, Anthony J Capobianco, Sander Dubovy, David Tse, Gaofeng Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To identify genomic mutations in lacrimal gland adenoid cystic carcinoma (LGACC) samples from patients.

Methods: Genomic DNA was extracted from LGACC specimens. Whole exome sequencing (exome-seq) was conducted to screen for mutations. Capillary sequencing was performed to verify mutations in genes shared by multiple samples. Luciferase assays were used to evaluate functional consequences of NOTCH1 mutations.

Results: The mutation profile of LGACC was complicated. The most frequently mutated gene observed (28.6%) was bromodomain PHD finger transcription factor (BPTF). No mutation was identified in common cancer genes such as TP53, KRAS, and BRAF. However, mutations predicted to be functionally severe were accumulated in the Notch signaling pathway including NOTCH1 and NOTCH2, of which mutations have been reported in head/neck adenoid cystic carcinoma (ACC). Of 14 LGACC samples, five samples carry mutations in Notch pathway genes. Capillary sequencing verified all the mutations in the two NOTCH genes identified by exome-seq. Compared to the wild-type NOTCH1, three frame shifting mutations and two missense mutations (C387W and L1600Q) increased luciferase activity approximately 10- to 25-fold.

Conclusions: Major genomic mutation profiles in LGACC were uncovered by exome-seq. Although preliminary in nature, the Notch pathway could be a potential therapeutic target for LGACC.

Original languageEnglish (US)
Pages (from-to)BIO240-BIO246
JournalInvestigative ophthalmology & visual science
Volume58
Issue number6
DOIs
StatePublished - May 1 2017

Fingerprint

Exome
Lacrimal Apparatus
Adenoid Cystic Carcinoma
Mutation
Luciferases
Genes
Neoplasm Genes
Missense Mutation

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma. / Sant, David W.; Tao, Wensi; Field, Matthew G.; Pelaez, Daniel; Jin, Ke; Capobianco, Anthony J; Dubovy, Sander; Tse, David; Wang, Gaofeng.

In: Investigative ophthalmology & visual science, Vol. 58, No. 6, 01.05.2017, p. BIO240-BIO246.

Research output: Contribution to journalArticle

@article{77ad2cc25ac04711b579648e6777e3ac,
title = "Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma",
abstract = "Purpose: To identify genomic mutations in lacrimal gland adenoid cystic carcinoma (LGACC) samples from patients.Methods: Genomic DNA was extracted from LGACC specimens. Whole exome sequencing (exome-seq) was conducted to screen for mutations. Capillary sequencing was performed to verify mutations in genes shared by multiple samples. Luciferase assays were used to evaluate functional consequences of NOTCH1 mutations.Results: The mutation profile of LGACC was complicated. The most frequently mutated gene observed (28.6{\%}) was bromodomain PHD finger transcription factor (BPTF). No mutation was identified in common cancer genes such as TP53, KRAS, and BRAF. However, mutations predicted to be functionally severe were accumulated in the Notch signaling pathway including NOTCH1 and NOTCH2, of which mutations have been reported in head/neck adenoid cystic carcinoma (ACC). Of 14 LGACC samples, five samples carry mutations in Notch pathway genes. Capillary sequencing verified all the mutations in the two NOTCH genes identified by exome-seq. Compared to the wild-type NOTCH1, three frame shifting mutations and two missense mutations (C387W and L1600Q) increased luciferase activity approximately 10- to 25-fold.Conclusions: Major genomic mutation profiles in LGACC were uncovered by exome-seq. Although preliminary in nature, the Notch pathway could be a potential therapeutic target for LGACC.",
author = "Sant, {David W.} and Wensi Tao and Field, {Matthew G.} and Daniel Pelaez and Ke Jin and Capobianco, {Anthony J} and Sander Dubovy and David Tse and Gaofeng Wang",
year = "2017",
month = "5",
day = "1",
doi = "10.1167/iovs.16-21097",
language = "English (US)",
volume = "58",
pages = "BIO240--BIO246",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "6",

}

TY - JOUR

T1 - Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma

AU - Sant, David W.

AU - Tao, Wensi

AU - Field, Matthew G.

AU - Pelaez, Daniel

AU - Jin, Ke

AU - Capobianco, Anthony J

AU - Dubovy, Sander

AU - Tse, David

AU - Wang, Gaofeng

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose: To identify genomic mutations in lacrimal gland adenoid cystic carcinoma (LGACC) samples from patients.Methods: Genomic DNA was extracted from LGACC specimens. Whole exome sequencing (exome-seq) was conducted to screen for mutations. Capillary sequencing was performed to verify mutations in genes shared by multiple samples. Luciferase assays were used to evaluate functional consequences of NOTCH1 mutations.Results: The mutation profile of LGACC was complicated. The most frequently mutated gene observed (28.6%) was bromodomain PHD finger transcription factor (BPTF). No mutation was identified in common cancer genes such as TP53, KRAS, and BRAF. However, mutations predicted to be functionally severe were accumulated in the Notch signaling pathway including NOTCH1 and NOTCH2, of which mutations have been reported in head/neck adenoid cystic carcinoma (ACC). Of 14 LGACC samples, five samples carry mutations in Notch pathway genes. Capillary sequencing verified all the mutations in the two NOTCH genes identified by exome-seq. Compared to the wild-type NOTCH1, three frame shifting mutations and two missense mutations (C387W and L1600Q) increased luciferase activity approximately 10- to 25-fold.Conclusions: Major genomic mutation profiles in LGACC were uncovered by exome-seq. Although preliminary in nature, the Notch pathway could be a potential therapeutic target for LGACC.

AB - Purpose: To identify genomic mutations in lacrimal gland adenoid cystic carcinoma (LGACC) samples from patients.Methods: Genomic DNA was extracted from LGACC specimens. Whole exome sequencing (exome-seq) was conducted to screen for mutations. Capillary sequencing was performed to verify mutations in genes shared by multiple samples. Luciferase assays were used to evaluate functional consequences of NOTCH1 mutations.Results: The mutation profile of LGACC was complicated. The most frequently mutated gene observed (28.6%) was bromodomain PHD finger transcription factor (BPTF). No mutation was identified in common cancer genes such as TP53, KRAS, and BRAF. However, mutations predicted to be functionally severe were accumulated in the Notch signaling pathway including NOTCH1 and NOTCH2, of which mutations have been reported in head/neck adenoid cystic carcinoma (ACC). Of 14 LGACC samples, five samples carry mutations in Notch pathway genes. Capillary sequencing verified all the mutations in the two NOTCH genes identified by exome-seq. Compared to the wild-type NOTCH1, three frame shifting mutations and two missense mutations (C387W and L1600Q) increased luciferase activity approximately 10- to 25-fold.Conclusions: Major genomic mutation profiles in LGACC were uncovered by exome-seq. Although preliminary in nature, the Notch pathway could be a potential therapeutic target for LGACC.

UR - http://www.scopus.com/inward/record.url?scp=85028291279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028291279&partnerID=8YFLogxK

U2 - 10.1167/iovs.16-21097

DO - 10.1167/iovs.16-21097

M3 - Article

C2 - 28820917

AN - SCOPUS:85028291279

VL - 58

SP - BIO240-BIO246

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 6

ER -